Dynamic reprogramming of the kinome in response to targeted MEK inhibition in triple-negative breast cancer

Cell

Volumn 149, Issue 2, 2012, Pages 307-321

  Duncan, James S ^a   Whittle, Martin C ^a   Nakamura, Kazuhiro ^a   Abell, Amy N ^a   Midland, Alicia A ^b   Zawistowski, Jon S ^a   Johnson, Nancy L ^a   Granger, Deborah A ^a   Jordan, Nicole Vincent ^a   Darr, David B ^a   Usary, Jerry ^a   Kuan, Pei Fen ^c   Smalley, David M ^a   Major, Ben ^a   He, Xiaping ^a   Hoadley, Katherine A ^a   Zhou, Bing ^a   Sharpless, Norman E ^a   Perou, Charles M ^a   Kim, William Y ^a   Gomez, Shawn M ^b   Chen, Xin ^d   Jin, Jian ^d   Frye, Stephen V ^d   Earp, H Shelton ^a   Graves, Lee M ^a   Johnson, Gary L ^a   more..

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

^b NORTH CAROLINA STATE UNIVERSITY   (United States)

^c IL   (United States)

^d University of North Carolina   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

2 [4 (2 DIMETHYLAMINOETHOXY)PHENYL] 4 (1 HYDROXYIMINO 5 INDANYL) 5 (4 PYRIDINYL) 1H IMIDAZOLE; ANTINEOPLASTIC AGENT; MITOGEN ACTIVATED PROTEIN KINASE KINASE; MITOGEN ACTIVATED PROTEIN KINASE KINASE 2; MYC PROTEIN; PLX 4720; PROTEIN TYROSINE KINASE; SELUMETINIB; SORAFENIB; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN DEGRADATION; PROTEIN EXPRESSION; TRIPLE NEGATIVE BREAST CANCER;

MUS;

EID: 84859765844     PISSN: 00928674     EISSN: 10974172     Source Type: Journal    
DOI: 10.1016/j.cell.2012.02.053     Document Type: Article

References (33)

1. D.N. Amin, N. Sergina, D. Ahuja, M. McMahon, J.A. Blair, D. Wang, B. Hann, K.M. Koch, K.M. Shokat, and M.M. Moasser Resiliency and vulnerability in the HER2-HER3 tumorigenic driver Sci. Transl. Med. 2 2010 16ra17
2. M. Bantscheff, D. Eberhard, Y. Abraham, S. Bastuck, M. Boesche, S. Hobson, T. Mathieson, J. Perrin, M. Raida, and C. Rau Quantitative chemical proteomics reveals mechanisms of action of clinical ABL kinase inhibitors Nat. Biotechnol. 25 2007 1035 1044
3. G. Bianchi, S. Loibl, C. Zamagni, S. Salvagni, G. Raab, S. Siena, N. Laferriere, C. Peña, C. Lathia, L. Bergamini, and L. Gianni Phase II multicenter, uncontrolled trial of sorafenib in patients with metastatic breast cancer Anticancer Drugs 20 2009 616 624
4. S. Chandarlapaty, A. Sawai, M. Scaltriti, V. Rodrik-Outmezguine, O. Grbovic-Huezo, V. Serra, P.K. Majumder, J. Baselga, and N. Rosen AKT inhibition relieves feedback suppression of receptor tyrosine kinase expression and activity Cancer Cell 19 2011 58 71
5. H. Daub, J.V. Olsen, M. Bairlein, F. Gnad, F.S. Oppermann, R. Körner, Z. Greff, G. Kéri, O. Stemmann, and M. Mann Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle Mol. Cell 31 2008 438 448
6. J.A. Engelman, K. Zejnullahu, T. Mitsudomi, Y. Song, C. Hyland, J.O. Park, N. Lindeman, C.M. Gale, X. Zhao, and J. Christensen MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling Science 316 2007 1039 1043
7. O. Fedorov, S. Müller, and S. Knapp The (un)targeted cancer kinome Nat. Chem. Biol. 6 2010 166 169
8. R.S. Finn, M.F. Press, J. Dering, M. Arbushites, M. Koehler, C. Oliva, L.S. Williams, and A. Di Leo Estrogen receptor, progesterone receptor, human epidermal growth factor receptor 2 (HER2), and epidermal growth factor receptor expression and benefit from lapatinib in a randomized trial of paclitaxel with lapatinib or placebo as first-line treatment in HER2-negative or unknown metastatic breast cancer J. Clin. Oncol. 27 2009 3908 3915
9. J.T. Garrett, M.G. Olivares, C. Rinehart, N.D. Granja-Ingram, V. Sánchez, A. Chakrabarty, B. Dave, R.S. Cook, W. Pao, and E. McKinely Transcriptional and posttranslational up-regulation of HER3 (ErbB3) compensates for inhibition of the HER2 tyrosine kinase Proc. Natl. Acad. Sci. USA 108 2011 5021 5026
10. A.G. Gilmartin, M.R. Bleam, A. Groy, K.G. Moss, E.A. Minthorn, S.G. Kulkarni, C.M. Rominger, S. Erskine, K.E. Fisher, and J. Yang GSK1120212 (JTP-74057) is an inhibitor of MEK activity and activation with favorable pharmacokinetic properties for sustained in vivo pathway inhibition Clin. Cancer Res. 17 2011 989 1000
11. C.M. Johannessen, J.S. Boehm, S.Y. Kim, S.R. Thomas, L. Wardwell, L.A. Johnson, C.M. Emery, N. Stransky, A.P. Cogdill, and J. Barretina COT drives resistance to RAF inhibition through MAP kinase pathway reactivation Nature 468 2010 968 972
12. M.W. Karaman, S. Herrgard, D.K. Treiber, P. Gallant, C.E. Atteridge, B.T. Campbell, K.W. Chan, P. Ciceri, M.I. Davis, and P.T. Edeen A quantitative analysis of kinase inhibitor selectivity Nat. Biotechnol. 26 2008 127 132
13. F. Marampon, C. Ciccarelli, and B.M. Zani Down-regulation of c-Myc following MEK/ERK inhibition halts the expression of malignant phenotype in rhabdomyosarcoma and in non muscle-derived human tumors Mol. Cancer 5 2006 31
14. R. Nazarian, H. Shi, Q. Wang, X. Kong, R.C. Koya, H. Lee, Z. Chen, M.K. Lee, N. Attar, and H. Sazegar Melanomas acquire resistance to B-RAF(V600E) inhibition by RTK or N-RAS upregulation Nature 468 2010 973 977
15. F.S. Oppermann, F. Gnad, J.V. Olsen, R. Hornberger, Z. Greff, G. Kéri, M. Mann, and H. Daub Large-scale proteomics analysis of the human kinome Mol. Cell. Proteomics 8 2009 1751 1764
16. S.K. Oster, W.W. Marhin, C. Asker, L.M. Facchini, P.A. Dion, K. Funa, M. Post, J.M. Sedivy, and L.Z. Penn Myc is an essential negative regulator of platelet-derived growth factor beta receptor expression Mol. Cell. Biol. 20 2000 6768 6778
17. D.A. Ritt, D.M. Monson, S.I. Specht, and D.K. Morrison Impact of feedback phosphorylation and Raf heterodimerization on normal and mutant B-Raf signaling Mol. Cell. Biol. 30 2010 806 819
18. V.S. Rodrik-Outmezguine, S. Chandarlapaty, N.C. Pagano, P.I. Poulikakos, M. Scaltriti, E. Moskatel, J. Baselga, S. Guichard, and N. Rosen mTOR kinase inhibition causes feedback-dependent biphasic regulation of AKT signaling Cancer Discov. 1 2011 248 259
19. S. Marchetti, C. Gimond, J.C. Chambard, T. Touboul, D. Roux, J. Pouysségur, and G. Pags Extracellular signal-regulated kinases phosphorylate mitogen-activated protein kinase phosphatase 3/DUSP6 at serines 159 and 197, two sites critical for its proteasomal degradation Mol. Cell. Biol. 25 2005 854 864
20. R. Sears, F. Nuckolls, E. Haura, Y. Taya, K. Tamai, and J.R. Nevins Multiple Ras-dependent phosphorylation pathways regulate Myc protein stability Genes Dev. 14 2000 2501 2514
21. T. Sun, N. Aceto, K.L. Meerbrey, J.D. Kessler, C. Zhou, I. Migliaccio, D.X. Nguyen, N.N. Pavlova, M. Botero, and J. Huang Activation of multiple proto-oncogenic tyrosine kinases in breast cancer via loss of the PTPN12 phosphatase Cell 144 2011 703 718
22. J. Villanueva, A. Vultur, J.T. Lee, R. Somasundaram, M. Fukunaga-Kalabis, A.K. Cipolla, B. Wubbenhorst, X. Xu, P.A. Gimotty, and D. Kee Acquired resistance to BRAF inhibitors mediated by a RAF kinase switch in melanoma can be overcome by cotargeting MEK and IGF-1R/PI3K Cancer Cell 18 2010 683 695
23. I. Wierstra, and J. Alves The c-myc Promoter: Still MysterY and Challenge Adv. Cancer Res. 99 2008 113 333
24. Barker, A.J.; Gibson, K.H.; Grundy, W.; Godfrey, A.A.; Barlow, J.J.; Healy, M.P.; Woodburn, J.R.; Ashton, S.E.; Curry, B.J.; Scarlett, L.; et al. (2001). Studies leading to the identification of ZD1839 (IRESSA): an orally active, selective epidermal growth factor receptor tyrosine kinase inhibitor targeted to the treatment of cancer. Bioorg. Med. Chem. Lett. 11, 1911-1914.
25. Das J.; Chen, P.; Norris, D.; Padmanabha, R.; Lin, J.; Moquin, R.V.; Shen, Z.; Cook, L.S.; Doweyko, A.M.; Pitt, S.; et al. (2006). 2-Aminothiazole as a novel kinase inhibitor template. Structure-activity relationship studies toward the discovery of N-(2-chloro-6-methylphenyl)-2-[[6-[4-(2-hydroxyethyl)-1- piperazinyl)]-2-methyl-4-pyrimidinyl]amino)]-1,3-thiazole-5-carboxamide (dasatinib, BMS-354825) as a potent pan-Src kinase inhibitor. J. Med. Chem. 49, 6819-6832.
26. Daub, H.; Olsen, J.V.; Bairlein, M.; Gnad, F.; Oppermann, F.S.; Körner, R.; Greff, Z.; Kéri, G.; Stemmann, O.; and Mann, M. (2008). Kinase-selective enrichment enables quantitative phosphoproteomics of the kinome across the cell cycle. Mol. Cell 31, 438-448.
27. Gallagher, T.F.; Seibel, G.L.; Kassis, S.; Laydon, J.T.; Blumenthal, M.J.; Lee, J.C.; Lee, D.; Boehm, J.C.; Fier-Thompson, S.M.; Abt, J.W.; et al. (1997). Regulation of stress-induced cytokine production by pyridinylimidazoles; inhibition of CSBP kinase. Bioorg. Med. Chem. 5, 49-64.
28. Klutchko, S.R.; Hamby, J.M.; Boschelli, D.H.; Wu, Z.; Kraker, A.J.; Amar, A.M.; Hartl, B.G.; Shen, C.; Klohs, W.D.; Steinkampf, R.W.; et al. (1998). 2-Substituted aminopyrido[2,3-d]pyrimidin-7(8H)-ones. Structure-activity relationships against selected tyrosine kinases and in vitro and in vivo anticancer activity. J. Med. Chem. 41, 3276-3292.
29. Langmead, B.; Trapnell, C.; Pop, M.; and Salzberg, S.L. (2009). Ultrafast and memory-efficient alignment of short DNA sequences to the human genome. Genome Biol. 10, R25.
30. Mortazavi, A.; Williams, B.A.; McCue, K.; Schaeffer, L.; and Wold, B. (2008). Mapping and quantifying mammalian transcriptomes by RNA-Seq. Nat. Methods 5, 621-628.
31. Ong, S.E.; Blagoev, B.; Kratchmarova, I.; Kristensen, D.B.; Steen, H.; Pandey, A.; and Mann, M. (2002). Stable isotope labeling by amino acids in cell culture, SILAC, as a simple and accurate approach to expression proteomics. Mol. Cell. Proteomics 1, 376-386.
32. Schteynberg, D.; Deutsch, E.W.; Lam, H.; Eng, J.K.; Sun, Z.; Tasman, N.; Mendoza, L.; Moritz, R.L.; Aebersold, R.; Nesvizhskii, A.I. (2011). iProphet: multi-level integrative analysis of shotgun proteomic data improves peptide and protein identification rates and error estimates. Mol. Cell. Proteomics 10, M111.007690.
33. Thingholm, T.E.; Jørgensen, T.J.; Jensen, O.N.; and Larsen, M.R. (2006). Highly selective enrichment of phosphorylated peptides using titanium dioxide. Nat. Protoc. 1, 1929-1935.